Engineered immune cells take on recurrent brain tumors
Disease control
Ongoing
This early-phase study tests a new treatment called CHM-1101 for people with a type of aggressive brain cancer (glioblastoma) that has returned or worsened. The treatment uses the patient's own immune cells, modified to better find and attack cancer cells that have a specific mar…
Phase: PHASE1 • Sponsor: Chimeric Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:44 UTC